RIGL
Rigel Pharmaceuticals Inc
47.20$
+0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 82.4% | 84.7% | 73.1% | 73.8% | 76.4% | 82.4% | 83.3% | 84.8% | 88.6% | 46.8% | 46.4% | 35.6% | |
| 39.4% | 28.0% | 20.2% | 28.1% | 37.1% | 34.6% | 26.0% | 25.8% | 20.0% | 7.9% | 4.8% | 11.7% | |
| 54.1% | 48.6% | 39.2% | 38.2% | 43.8% | 47.2% | 43.8% | 52.4% | 56.5% | 30.2% | 29.1% | 18.3% | |
| 20.4% | 26.1% | 21.7% | 22.5% | 21.9% | 25.4% | 23.6% | 19.3% | 18.9% | 10.1% | 9.9% | 10.8% | |
| 5.3% | 4.7% | 5.2% | 6.3% | 3.4% | 3.7% | 2.6% | 5.0% | 8.5% | 2.2% | 2.3% | 2.8% | |
| 12.3% | 11.8% | 22.8% | 22.0% | 19.9% | 16.5% | 15.1% | 12.5% | 10.4% | 4.8% | 4.8% | 18.0% | |
| 127.6% | 124.4% | 125.0% | 123.3% | 110.5% | 98.0% | 89.4% | 60.4% | 51.5% | 23.8% | 20.8% | 18.3% | |
| 41.9% | 45.4% | 57.9% | 45.7% | 39.0% | 38.6% | 37.9% | 41.9% | 38.9% | 19.3% | 17.7% | 18.3% | |
| 0.6% | 6.8% | 12.2% | 0.5% | 0.3% | 4.6% | 8.7% | 11.1% | 12.5% | 5.9% | 6.0% | 7.7% | |
| 6.9% | 6.1% | 7.3% | 4.8% | 2.7% | 2.0% | 2.2% | 3.5% | 1.6% | 1.4% | 0.9% | 0.8% | |
| 51.7% | 44.7% | 35.5% | 46.5% | 42.9% | 32.0% | 25.5% | 18.1% | 12.4% | 4.4% | 3.0% | – | |
| -27.6% | -24.4% | -25.0% | -23.3% | -10.5% | 2.0% | 10.6% | 39.6% | 48.5% | 76.2% | 79.2% | 81.6% | |
| -1,221.2% | -1,200.7% | -1,119.0% | -1,103.4% | -1,007.3% | -847.7% | -783.4% | -638.0% | -532.3% | -199.2% | -201.0% | -191.4% | |
| 15.1% | 14.9% | 13.8% | 13.7% | 12.7% | 11.0% | 10.3% | 8.8% | 7.9% | 3.7% | 3.9% | 3.8% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.